Joseph Castillo
Biomarker Technologies (China)(CN)
Publications by Year
Research Areas
Cancer Mechanisms and Therapy, Peptidase Inhibition and Analysis, Multiple Myeloma Research and Treatments, Phytochemical compounds biological activities, Prostate Cancer Treatment and Research
Most-Cited Works
- → Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation(2013)161 cited
- → Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers(2014)111 cited
- → Anemia and perinatal death result from loss of the murine ecotropic retrovirus receptor mCAT-1.(1997)84 cited
- → Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies(2015)74 cited
- → Stem cell factor in combination with granulocyte colony-stimulating factor (CSF) or granulocyte-macrophage CSF synergistically increases granulopoiesis in vivo(1991)66 cited
- → Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer(2014)61 cited
- → Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors(2013)53 cited
- → Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer(2020)19 cited
- → Abstract 5194: Pim2 is required for maintaining Multiple Myeloma cell proliferation through modulating mTORC1 pathway.(2013)1 cited
- → Abstract 2149: Association of tumor fusion burden with immune presence and androgen sensitivity in prostate cancer(2019)